Unión Europea - español - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - agentes antineoplásicos - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Unión Europea - español - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - neoplasmas ováricos - agentes antineoplásicos - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca está indicado como monoterapia para el tratamiento de mantenimiento de pacientes adultos con platino-sensible a la recaída de alto grado epitelial de ovario, de trompa de falopio o peritoneal primario de cáncer que están en la respuesta (completa o parcial) a la quimioterapia basada en platino.

Unión Europea - español - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - inmunológicos para équidos - caballos - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Unión Europea - español - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - leucemia-linfoma linfoblástica de células precursoras - agentes antineoplásicos - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Unión Europea - español - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - mieloma múltiple - agentes antineoplásicos - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Unión Europea - español - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - neoplasias de la mama - agentes antineoplásicos - talzenna está indicado como monoterapia para el tratamiento de pacientes adultos con línea germinal mutaciones brca1/2, que han her2-negativo localmente avanzado o metastásico, el cáncer de mama. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. los pacientes con receptores hormonales (rh) positivo de cáncer de mama deben haber sido tratadas con un endocrino antes de la terapia basada en, o ser considerados no aptos para el sistema endocrino de la terapia basada en.

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agentes antineoplásicos - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Unión Europea - español - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leucemia, mieloide - agentes antineoplásicos - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Unión Europea - español - EMA (European Medicines Agency)

intervet international b.v. - inactivado cepas de leptospira: l. interrogans serogrupo canicola serovar portland-vere (cepa ca-12-000); l. interrogans serogrupo icterohaemorrhagiae serovar copenhageni (cepa ic-02-001); l. interrogans serogrupo australis serovar bratislava (cepa como-05-073); l. kirschneri serogrupo serovar grippotyphosa dadas (cepa gr-01-005) - immunologicals para los miembros de la familia canidae, inactivada de vacunas bacterianas (incluyendo mycoplasma, toxoide tetánico y clamidia) - perros - para la inmunización activa de perros contra: l. interrogans serogrupo canicola serovar canicola a reducir la infección y la excreción urinaria;l. interrogans serogrupo icterohaemorrhagiae serovar copenhageni para reducir la infección y la excreción urinaria;l. interrogans serogrupo australis serovar bratislava a reducir la infección;l. kirschneri serogrupo grippotyphosa serovar bananal / lianguang para reducir la infección y la excreción urinaria.

Unión Europea - español - EMA (European Medicines Agency)

les laboratoires servier - dimaleato de pixantrona - linfoma, no hodgkin - agentes antineoplásicos - pixuvri está indicado como monoterapia para el tratamiento de pacientes adultos con linfomas de células b no hodgkin (nhl) agresivos y con recaídas múltiples o refractarios. el beneficio del tratamiento con pixantrona no se ha establecido en pacientes cuando se usa como quimioterapia de quinta línea o mayor en pacientes que son refractarios a la última terapia.